

Consider the RemeMG Study

MG is a rare autoimmune disease affecting about 700,000 people worldwide. In an autoimmune disease, the body's immune system mistakenly attacks its own healthy tissues. The current therapy for MG focuses on treating symptoms caused by the disease, like muscle weakness. However, these treatments do not always help relieve symptoms and can have side effects.

The focus of MG treatment is shifting from symptom relief to targeting the immune system, where the root cause lies.

The RemeMG Study is testing a study drug that targets the immune system to see what effect it may have on the daily lives of those who have MG.

Please discuss study participation with your treating doctor.



Thank you for taking an interest in the RemeMG Study. If you'd like more information about the study, please contact:

Principal Investigator: Dr. Melanie Taylor
Study Coordinator: Katie Schwass
Phone: 616-685-5437
Email: katherine.schwass@trinity-health.org
Site: Trinity Health Grand Rapids Hospital



RC18G006_Brochure_US Eng_V1.0_09MAY2024

Are You Living With Myasthenia Gravis (MG)?



Explore whether the RemeMG Study is right for you




About the RemeMG Study

The RemeMG Study will test how safe and effective a study drug called telitacicept may be in adults living with generalized Myasthenia Gravis (gMG).

After screening, participants who qualify will be randomly chosen (as if by the flip of a coin) to take either the study drug or placebo for the first 24 weeks treatment period. The placebo looks the same but contains no active ingredients. For this period, you will have a 50% chance of getting either one.


Both are taken as weekly injections, some of which may be self-injected (or given by a caregiver) at home between study visits. You can choose whether to do the injection at home or at a study site.

If you complete the first treatment period, you will have the option of taking part in an extension treatment period for 48 weeks if you qualify, during which everyone will take the study drug. No placebo will be given.



Length of Study

Taking part in the RemeMG Study lasts up to 84 weeks and includes:



Who Can Join the RemeMG Study?

You may be able to join if you:

- Are 18 years or older
- Have been diagnosed with gMG
- Do not have any other autoimmune diseases, like rheumatoid arthritis or Sjogren's syndrome

Other requirements need to be met to join. Please discuss study participation with your treating doctor.

Why Take Part?

In addition to possibly benefiting from the study drug, joining the RemeMG Study will help us learn about treating MG and could help other patients with MG in the future.

If you qualify and take part, you may receive:

- The study drug
- Close medical care and follow-up throughout the study
- Reimbursement for reasonable study-related expenses (for example, travel and parking)

About Clinical Studies

A clinical research study (also called a trial) is carefully supervised research that is done before a study drug may become available to the public.

- Studies follow certain rules to protect the rights, safety, well-being, and privacy of participants.
- The results help government officials decide if a medication or other product is safe and should be available to patients.
- Studies are the only way to bring about new medical treatments to improve patient care.

Joining the RemeMG Study is completely up to you. Deciding not to take part will not affect your usual medical care now or in the future. If you take part, you can decide to leave the study at any time and for any reason.

